Predictive Value of microRNA in Thyroid Cytologies of Undetermined Type

Launched by INSTITUT DU CANCER DE MONTPELLIER - VAL D'AURELLE · Feb 24, 2020

Keywords

ClinConnect Summary

**Clinical Trial Summary: Predictive Value of microRNA in Thyroid Cytologies of Undetermined Type**

This clinical trial is studying a special type of genetic material called microRNA to help doctors better understand thyroid nodules that are uncertain in nature. Some thyroid nodules can be confusing, and usually, doctors use ultrasound and tissue samples to determine if they are cancerous or not. In this study, researchers will look at the microRNA from samples of 70 patients to see if it can help predict the nature of these nodules more accurately. This could lead to better treatment decisions for patients with thyroid issues.

To participate in this trial, adults aged 18 and older who need a thyroid ultrasound and have specific types of nodules (classified as Bethesda 3, 4, and 5) may be eligible. Participants will need to provide their consent and be part of the French healthcare system. Those who have serious mental or medical conditions, or who have received certain cancer treatments recently, may not qualify. If you join the study, you will help researchers find out if the microRNA testing can improve how doctors diagnose thyroid nodules, potentially benefiting many patients in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Man or woman whose Age is ≥ 18 years
• • 2. Patient requiring ultrasound for thyroid nodule scanning with established indication of FNAC
• • 3. Patient with Bethesda 3, 4 and 5 thyroid nodule
• • 4. Informed patient and signed informed consent received
• • 5. Patient affiliated to a French medical coverage system
• Exclusion Criteria:
• • 1. Patient under guardianship, curatorship or safeguarding of justice
• • 2. Patient whose medical or psychological conditions do not permit them to complete the study or to sign the consent,
• • 3. Patient with metastatic cancer distinct from thyroid cancer
• • 4. Patient who has stopped treatment (chemotherapy / immunotherapy) for cancer for less than 6 months.